Pharmaceutical company secures additional patent for nasal spray

  • Evoke Pharma shares rise over 10% on new Gimoti U.S. patent
  • New patent provides additional intellectual-property protections for Gimoti nasal spray
  • Evoke plans to seek listing of the patent in FDA’s “Orange Book” for added protection
  • Gimoti approved by FDA in 2020 for treatment of acute and recurrent diabetic gastroparesis

Evoke Pharma shares surged more than 10% after the company announced the acquisition of a new U.S. patent for its Gimoti nasal spray. The patent specifically covers nasal formulations of metoclopramide, the active ingredient in Gimoti, and offers increased intellectual-property protections. Evoke Pharma intends to list the patent in the FDA’s "Orange Book," a strategic move that could provide further defense against generic competition. Gimoti, which received FDA approval in 2020, is used for the treatment of acute and recurrent diabetic gastroparesis.

Factuality Level: 8
Factuality Justification: The article provides factual information about Evoke Pharma securing an additional U.S. patent for its Gimoti nasal spray and the potential benefits it brings in terms of intellectual property protection and potential protection from generic competition. The information is straightforward and does not contain any obvious bias or misleading information.
Noise Level: 7
Noise Justification: The article provides some relevant information about Evoke Pharma securing an additional U.S. patent for its Gimoti nasal spray. However, it lacks in-depth analysis, scientific rigor, and evidence to support its claims. The article also does not explore the consequences of this development on the company or the pharmaceutical industry. Overall, it contains some noise and filler content.
Financial Relevance: Yes
Financial Markets Impacted: The news article pertains to Evoke Pharma, a specialty pharmaceutical company. The rise in Evoke Pharma shares indicates potential impact on the company’s stock price and the pharmaceutical market.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article does not mention any extreme events or their impact.
Public Companies: Evoke Pharma (N/A)
Key People:

Reported publicly: www.marketwatch.com